Anesth Pain Med.  2016 Apr;11(2):166-171. 10.17085/apm.2016.11.2.166.

Comparison of prophylactic anti-emetic effects of ramosetron between single bolus administration and continuous infusion following bolus administration

• Doo AR
• Oh SM
• Kim BG
• Ko S

• KMID: 2358479
• DOI: http://doi.org/10.17085/apm.2016.11.2.166

Abstract

BACKGROUND
The authors hypothesized that the continuous infusion of ramosetron 0.15 mg following a 0.15 mg bolus administration would maintain higher 5-hydroxytryptamine type 3 receptor occupancy levels and be more effective in preventing postoperative nausea and vomiting (PONV) than a 0.3 mg single bolus administration. We conducted a study to compare the efficacy of single bolus ramosetron administration with the combination of continuous infusion following intravenous bolus administration for PONV prophylaxis.
METHODS
One hundred and fifty female patients undergoing thyroidectomy were allocated randomly to one of three groups to receive a placebo (Group 1, n = 49), 0.3 mg of IV ramosetron (Group 2, n = 53), or the continuous infusion of 0.15 mg ramosetron following a bolus administration of 0.15 mg of ramosetron (Group 3, n = 48). Anesthesia was maintained with sevoflurane and N2O. The incidence of PONV, nausea severity, and use of rescue antiemetics during the postoperative 24 hours were recorded.
RESULTS
Group 1 showed higher incidences of PONV during the postoperative 24 hour than Group 2 (81% vs. 58%, P = 0.02) and Group 3 (81% vs. 48%, P < 0.01), but there was no difference between Groups 2 and 3 (P = 0.39). The use of rescue antiemetics was significantly lower in Groups 2 and 3 than Group 1 during the postoperative 6 to 24 hours.
CONCLUSIONS
There were no significant differences of incidence and severity of PONV between ramosetron 0.3 mg single bolus administration and the combination of ramosetron infusion after 0.15 mg bolus administration.

Keyword

Morphine; Patient-controlled analgesia; Postoperative nausea and vomiting; Ramosetron; Thyroidectomy

MeSH Terms

Analgesia, Patient-Controlled
Anesthesia
Antiemetics*
Female
Humans
Incidence
Morphine
Nausea
Postoperative Nausea and Vomiting
Serotonin
Thyroidectomy
Antiemetics
Morphine
Serotonin

Reference

1. Rose JB, Watcha MF. Postoperative nausea and vomiting in paediatric patients. Br J Anaesth. 1999; 83:104–17. DOI: 10.1093/bja/83.1.104.

2. Ewalenko P, Janny S, Dejonckheere M, Andry G, Wyns C. Antiemetic effect of subhypnotic doses of propofol after thyroidectomy. Br J Anaesth. 1996; 77:463–7. DOI: 10.1093/bja/77.4.463. PMID: 8942329.

3. Yamada Y, Sugiura M, Higo K, Ozeki T, Takayanagi R, Okuyama K, et al. Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol. 2004; 54:185–90. DOI: 10.1007/s00280-004-0798-x. PMID: 15168080.

4. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc). 2002; 38:75–89. DOI: 10.1358/dot.2002.38.2.820104.

5. Ogata A, Yamada Y, Sugiura M, Takayanagi R, Sawada Y, Iga T. Analysis of 5-HT3 receptor antagonist, ramosetron hydrochloride, based on receptor occupancy considering its active metabolite. Yakugaku Zasshi. 2001; 121:793–8. DOI: 10.1248/yakushi.121.793. PMID: 11725547.

6. Choi YK, Kim HJ, Park SW, Kim KS. The optimal anti-emetic dose of ramosetron for prevention of postoperative nausea and vomiting following gynecolgic surgery. Korean J Anesthesiol. 2008; 54:538–43. DOI: 10.4097/kjae.2008.54.5.538.

7. Lee D, Kim JY, Shin JW, Ku CH, Park YS, Kwak HJ. The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia. J Anesth. 2009; 23:46–50. DOI: 10.1007/s00540-008-0693-4. PMID: 19234822.

8. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999; 91:693–700. DOI: 10.1097/00000542-199909000-00022. PMID: 10485781.

9. Apfel CC, Roewer N, Korttila K. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand. 2002; 46:921–8. DOI: 10.1034/j.1399-6576.2002.460801.x. PMID: 12190791.

10. Kim YS, Hahm TS, Chung YH, Lee JJ. Involuntary movements after ramosetron injection during propofol anesthesia: a case report. Anesth Pain Med. 2011; 6:143–5.

11. Gauger PG, Shanks A, Morris M, Greenfield ML, Burney RE, O’Reilly M. Propofol decreases early postoperative nausea and vomiting in patients undergoing thyroid and parathyroid operations. World J Surg. 2008; 32:1525–34. DOI: 10.1007/s00268-008-9472-5. PMID: 18305999.

12. Sonner JM, Hynson JM, Clark O, Katz JA. Nausea and vomiting following thyroid and parathyroid surgery. J Clin Anesth. 1997; 9:398–402. DOI: 10.1016/S0952-8180(97)00069-X.

13. Vari A, Gazzanelli S, Cavallaro G, De Toma G, Tarquini S, Guerra C, et al. Post-operative nausea and vomiting (PONV) after thyroid surgery: a prospective, randomized study comparing totally intravenous versus inhalational anesthetics. Am Surg. 2010; 76:325–8. PMID: 20349666.

14. White LA, Vanarase M, Brockbank K, Barrett RF. Patient-controlled analgesia and postoperative nausea and vomiting: efficacy of a continuous infusion of ondansetron. Anaesthesia. 2001; 56:365–9. DOI: 10.1046/j.1365-2044.2001.01708-5.x. PMID: 11284826.

15. Kang JW, Park SK. Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting. Korean J Anesthesiol. 2014; 67:110–4. DOI: 10.4097/kjae.2014.67.2.110. PMID: 25237447. PMCID: PMC4166382.

16. Ho CL, Su WC, Hsieh RK, Lin ZZ, Chao TY. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol. 2010; 40:294–301. DOI: 10.1093/jjco/hyp169. PMID: 20026457.

17. Shi Y, He X, Yang S, Ai B, Zhang C, Huang D, et al. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemotherapy. 2007; 53:44–50. DOI: 10.1159/000098418. PMID: 17202811.

18. Kamato T, Ito H, Nagakura Y, Nishida A, Yuki H, Yamano M, et al. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Pharmacol. 1993; 238:369–76. DOI: 10.1016/0014-2999(93)90868-I.

19. Ryu JH, Jeon YT, Hwang JW, Oh AY, Moon JY, Ro YJ, et al. Intravenous, oral, and the combination of intravenous and oral ramosetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, controlled trial. Clin Ther. 2011; 33:1162–72. DOI: 10.1016/j.clinthera.2011.07.018. PMID: 21856001.

20. Lee DC, Kwak HJ, Kim HS, Choi SH, Lee JY. The preventative effect of ramosetron on postoperative nausea and vomiting after total thyroidectomy. Korean J Anesthesiol. 2011; 61:154–8. DOI: 10.4097/kjae.2011.61.2.154. PMID: 21927687. PMCID: PMC3167136.

21. Ryu J, So YM, Hwang J, Do SH. Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Surg Endosc. 2010; 24:812–7. DOI: 10.1007/s00464-009-0670-5. PMID: 19707823.

22. Lee JW, Park HJ, Choi J, Park SJ, Kang H, Kim EG. Comparison of ramosetron’s and ondansetron’s preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy. Korean J Anesthesiol. 2011; 61:488–92. DOI: 10.4097/kjae.2011.61.6.488. PMID: 22220226. PMCID: PMC3249571.